Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Wollenberg A, et al. Among authors: jensen tn. Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. Br J Dermatol. 2021. PMID: 33000465 Free PMC article. Clinical Trial.
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, Hijnen D, Jensen TN, Bang B, Olsen CK, Kurbasic A, Weidinger S; ECZTRA 3 study investigators. Silverberg JI, et al. Among authors: jensen tn. Br J Dermatol. 2021 Mar;184(3):450-463. doi: 10.1111/bjd.19573. Epub 2021 Feb 22. Br J Dermatol. 2021. PMID: 33000503 Free PMC article. Clinical Trial.
The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices.
Dale E, Grunnet M, Pehrson AL, Frederiksen K, Larsen PH, Nielsen J, Stensbøl TB, Ebert B, Yin H, Lu D, Liu H, Jensen TN, Yang CR, Sanchez C. Dale E, et al. Among authors: jensen tn. Brain Res. 2018 Jun 15;1689:1-11. doi: 10.1016/j.brainres.2017.12.025. Epub 2017 Dec 21. Brain Res. 2018. PMID: 29274875
Atomic structure of a spinel-like transition Al2O3(100) surface.
Jensen TN, Meinander K, Helveg S, Foster AS, Kulju S, Musso T, Lauritsen JV. Jensen TN, et al. Phys Rev Lett. 2014 Sep 5;113(10):106103. doi: 10.1103/PhysRevLett.113.106103. Epub 2014 Sep 4. Phys Rev Lett. 2014. PMID: 25238371
11 results